PLAU and neoplasm: Therefore, the Tumor Marker Guideline of the American Society of Clinical Oncology (ASCO) recommended uPA biomarker testing by ELISA to assess the risk of recurrence in node negative breast cancer patients and to decide individually if adjuvant chemotherapy is beneficial after surgery [8].